Plunkett Research Online: Oncternal Therapeutics Inc

ONCTERNAL THERAPEUTICS INC (ONCT:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyro.....



Oncternal Therapeutics Inc
Ticker: ONCT
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 858 434-1113
Fax: 858 408-3010
Address: 12230 El Camino Real
Suite 230
San Diego, CA 92130 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceutical Preparation Manufacturing
Contacts Description
James BreitmeyerCEO/Director/President
Richard VincentCFO/Treasurer
See More
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyro.....See More See More

Auditor: BDO USA, LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202320222021202020192018
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
NameTitleSalary (US$)Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: